In its 13F for Q3 2024 (holdings as of September 30, 2024, filed October 30, 2024), Rosalind Advisors, Inc. reported 29 stock positions worth $150.7 million . Its top holding was Delcath Systems (DCTH) at 14.1% of the portfolio, followed by Myomo (MYO, 8.0% ) and Cormedix (CRMD, 7.9% ). Compared with Q2 2024, it opened 3 new positions, sold out of 9, added to 10 and reduced 11. The biggest buy was a new position in Cormedix (CRMD) and the biggest sale an exit from Viridian Therapeutics (VRDN).
Location TORONTO, A6
CIK 0001622627
Portfolio Value $150.7M (Q3 2024) Holdings 29 stocks · $150.7M Holdings quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock % Of Portfolio ▼ Shares Held Total Value Change vs Q2 2024 DCTH Delcath Systems Inc. 2,650,389 $21.2M No change MYO Myomo Inc. 3,021,391 $12.1M Add +13.4% CRMD Cormedix Inc. 1,475,000 $11.9M New ABEO Abeona Therapeutics Inc. 1,832,000 $11.6M Add +4.7% MDWD Mediwound Ltd. 628,050 $11.3M Add +22.3% CYBIN INC 1,075,105 $9.6M Reduce -94.4% XERS Xeris Biopharma Holdings Inc. 3,104,995 $8.8M Reduce -0.5% VRNA Verona Pharma Ltd. 275,000 $7.9M Add +10.0% CLRB Cellectar Biosciences Inc. 3,671,550 $7.9M Add +35.7% OCUL Ocular Therapeutix Inc. 885,000 $7.7M Add +18.0% NSPR Inspiremd Inc. 2,514,046 $6.7M Add +0.0% OPTINOSE INC 8,287,503 $5.6M Add +9.8% CMPS Compass Pathways PLC 781,423 $4.9M Add +6.5% PROF Profound Medical Corp. 485,973 $3.9M Reduce -8.9% KALV Kalvista Pharmaceuticals Inc. 303,864 $3.5M Reduce -10.1% TRVI Trevi Therapeutics Inc. 750,000 $2.5M Reduce -46.1% OTLK Outlook Therapeutics Inc. 450,000 $2.4M No change PYPD Polypid Ltd. 679,168 $2.3M Add +63.0% VERU Veru Inc. 2,694,503 $2.1M Reduce -0.1% ABVX Abivax SA-ADR 139,983 $1.6M Reduce -63.0% OWLT Owlet Inc. 270,000 $1.2M New KPRX Kiora Pharmaceuticals Inc. 255,555 $935K No change FBIO Fortress Biotech Inc. 502,828 $727K Reduce -17.3% BFRI Biofrontera Inc. 495,490 $659K Reduce -1.7% TLPH Talphera Inc. 758,966 $650K No change DERM Journey Medical Corp. 105,917 $598K Reduce -7.2% NAMS Newamsterdam Pharma Co. NV 10,123 $168K No change CLEARSIDE BIOMEDICAL INC 127,220 $162K Reduce -95.1% VOR Vor Biopharma Inc. 76,685 $54K New
Options reported separately and not counted above: CORMEDIX INC calls ($3.6M), CASSAVA SCIENCES INC puts ($1.5M), QQQ puts ($221K), XBI puts ($164K).
Portfolio Sells Q2 2024 → Q3 2024 Portfolio Sells quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q2 2024 % Of Portfolio Change To Portfolio ▲ VRDN Viridian Therapeutics Inc. Sold out 0.00% −3.09 ABVX Abivax SA-ADR Reduce -63.0% 1.07% −2.89 CLEARSIDE BIOMEDICAL INC Reduce -95.1% 0.11% −2.56 TRVI Trevi Therapeutics Inc. Reduce -46.1% 1.66% −1.62 PROF Profound Medical Corp. Reduce -8.9% 2.57% −0.97 RZLT Rezolute Inc. Sold out 0.00% −0.85 KALV Kalvista Pharmaceuticals Inc. Reduce -10.1% 2.33% −0.81 GERN Geron Corp. Sold out 0.00% −0.67 UNICYCIVE THERAPEUTICS INC Sold out 0.00% −0.62 SPRB Spruce Biosciences Inc. Sold out 0.00% −0.62 VERU Veru Inc. Reduce -0.1% 1.37% −0.42 XAIR Beyond Air Inc. Sold out 0.00% −0.38 FBIO Fortress Biotech Inc. Reduce -17.3% 0.48% −0.34 LYRA Lyra Therapeutics Inc. Sold out 0.00% −0.23 DERM Journey Medical Corp. Reduce -7.2% 0.40% −0.11 BTAIQ Bioxcel Therapeutics Inc. Sold out 0.00% −0.04 TNXP Tonix Pharmaceuticals Holdin Sold out 0.00% −0.02 BFRI Biofrontera Inc. Reduce -1.7% 0.44% +0.08 XERS Xeris Biopharma Holdings Inc. Reduce -0.5% 5.87% +0.32 CYBIN INC Reduce -94.4% 6.34% +2.21
Portfolio Buys Q2 2024 → Q3 2024 Portfolio Buys quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q2 2024 % Of Portfolio Change To Portfolio ▼ CRMD Cormedix Inc. New 7.91% +7.91 VRNA Verona Pharma Ltd. Add +10.0% 5.25% +2.39 ABEO Abeona Therapeutics Inc. Add +4.7% 7.68% +1.81 MYO Myomo Inc. Add +13.4% 8.04% +1.27 MDWD Mediwound Ltd. Add +22.3% 7.53% +1.22 OCUL Ocular Therapeutix Inc. Add +18.0% 5.11% +1.05 OWLT Owlet Inc. New 0.80% +0.80 PYPD Polypid Ltd. Add +63.0% 1.55% +0.13 VOR Vor Biopharma Inc. New 0.04% +0.04 CLRB Cellectar Biosciences Inc. Add +35.7% 5.21% −0.14 CMPS Compass Pathways PLC Add +6.5% 3.27% −0.24 NSPR Inspiremd Inc. Add +0.0% 4.47% −0.49 OPTINOSE INC Add +9.8% 3.68% −2.52
Options Activity Q2 2024 → Q3 2024 Security Type Change vs Q2 2024 Underlying Shares Value ▼ CORMEDIX INC call New 700,000 $3.6M CASSAVA SCIENCES INC put Add +9902.7% 367,400 $1.5M ANNOVIS BIO INC put Sold out 24,154 $839Kbefore exit G1 THERAPEUTICS INC put Sold out 19,018 $305Kbefore exit QQQ Invesco QQQ Trust Series 1 put New 150,000 $221K XBI SS SPDR S&P Biotech ETF put Add +792.7% 200,000 $164K ALNYLAM PHARMACEUTICALS INC put Sold out 700 $0before exit
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings Quarter Positions 13F Reported Value Top Holdings Q2 2026 29 $266.2M DCTH, FENC, XERS, SVRA, VSTM Q1 2026 32 $244.1M DCTH, XERS, FENC, SVRA, PCVX Q4 2025 29 $274.5M DCTH, SVRA, FENC, XERS, VRDN Q3 2025 29 $283.0M DCTH, CYTK, FENC, VSTM, RZLT Q2 2025 29 $206.6M DCTH, FENC, CYTK, OCUL, IDYA Q1 2025 31 $205.2M DCTH, VSTM, XERS, MYO, IDYA Q4 2024 Amended 28 $185.7M DCTH, MYO, MDWD, CMRX, XERS Q3 2024 29 $150.7M DCTH, MYO, CRMD, ABEO, MDWD Q2 2024 35 $126.5M DCTH, MYO, MDWD, OPTINOSE INC, ABEO Q1 2024 31 $106.9M MYO, LYRA, MDWD, OPTINOSE INC, XERS